Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Correction: A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.

Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG.

Oncogene. 2018 Dec 3. doi: 10.1038/s41388-018-0587-3. [Epub ahead of print]

PMID:
30510231
2.

A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.

Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG.

Oncogene. 2018 Sep 7. doi: 10.1038/s41388-018-0488-5. [Epub ahead of print] Erratum in: Oncogene. 2018 Dec 3;:.

PMID:
30194451
3.

Correction: Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.

Chen R, Li Y, Buttyan R, Dong X.

Oncotarget. 2018 Jul 3;9(51):29842. doi: 10.18632/oncotarget.25759. eCollection 2018 Jul 3.

4.

Hedgehog in prostate cancer explained.

Buttyan R, Li N, Massah S.

Oncoscience. 2018 Apr 29;5(3-4):67-68. doi: 10.18632/oncoscience.405. eCollection 2018 Mar. No abstract available.

5.

Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3.

Li N, Truong S, Nouri M, Moore J, Al Nakouzi N, Lubik AA, Buttyan R.

Oncogene. 2018 Apr;37(17):2313-2325. doi: 10.1038/s41388-017-0098-7. Epub 2018 Feb 12.

6.

Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.

Chen R, Li Y, Buttyan R, Dong X.

Oncotarget. 2017 Jul 19;8(49):84863-84876. doi: 10.18632/oncotarget.19386. eCollection 2017 Oct 17. Erratum in: Oncotarget. 2018 Jul 3;9(51):29842.

7.

Semaphorin 3 C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells.

Tam KJ, Hui DHF, Lee WW, Dong M, Tombe T, Jiao IZF, Khosravi S, Takeuchi A, Peacock JW, Ivanova L, Moskalev I, Gleave ME, Buttyan R, Cox ME, Ong CJ.

Sci Rep. 2017 Sep 13;7(1):11501. doi: 10.1038/s41598-017-11914-6.

8.

A Role for the Hedgehog Effector Gli1 in Mediating Stent-induced Ureteral Smooth Muscle Dysfunction and Aperistalsis.

Janssen C, Buttyan R, Seow CY, Jäger W, Solomon D, Fazli L, Chew BH, Lange D.

Urology. 2017 Jun;104:242.e1-242.e8. doi: 10.1016/j.urology.2017.01.029. Epub 2017 Feb 8.

PMID:
28188758
9.

Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.

Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R.

Oncotarget. 2017 Mar 21;8(12):18949-18967. doi: 10.18632/oncotarget.14850.

10.

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.

Tse BWC, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG.

Oncogene. 2017 Jun 15;36(24):3417-3427. doi: 10.1038/onc.2016.482. Epub 2017 Jan 16.

11.

Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.

Lubik AA, Nouri M, Truong S, Ghaffari M, Adomat HH, Corey E, Cox ME, Li N, Guns ES, Yenki P, Pham S, Buttyan R.

Int J Cancer. 2017 Jan 15;140(2):358-369. doi: 10.1002/ijc.30450. Epub 2016 Oct 20.

12.

Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy.

Hayashi T, Gust KM, Wyatt AW, Goriki A, Jäger W, Awrey S, Li N, Oo HZ, Altamirano-Dimas M, Buttyan R, Fazli L, Matsubara A, Black PC.

Clin Cancer Res. 2016 Jun 15;22(12):2981-92. doi: 10.1158/1078-0432.CCR-15-2360. Epub 2016 Jan 14.

13.

FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer.

Han B, Qu Y, Jin Y, Yu Y, Deng N, Wawrowsky K, Zhang X, Li N, Bose S, Wang Q, Sakkiah S, Abrol R, Jensen TW, Berman BP, Tanaka H, Johnson J, Gao B, Hao J, Liu Z, Buttyan R, Ray PS, Hung MC, Giuliano AE, Cui X.

Cell Rep. 2015 Nov 3;13(5):1046-58. doi: 10.1016/j.celrep.2015.09.063.

14.

Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.

Levina E, Ji H, Chen M, Baig M, Oliver D, Ohouo P, Lim CU, Schools G, Carmack S, Ding Y, Broude EV, Roninson IB, Buttyan R, Shtutman M.

Oncotarget. 2015 May 30;6(15):13088-104.

15.

Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.

Li N, Chen M, Truong S, Yan C, Buttyan R.

Prostate. 2014 Oct;74(14):1400-10. doi: 10.1002/pros.22855. Epub 2014 Aug 11.

PMID:
25132524
16.

FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype.

DeGraff DJ, Grabowska MM, Case TC, Yu X, Herrick MK, Hayward WJ, Strand DW, Cates JM, Hayward SW, Gao N, Walter MA, Buttyan R, Yi Y, Kaestner KH, Matusik RJ.

Lab Invest. 2014 Jul;94(7):726-39. doi: 10.1038/labinvest.2014.64. Epub 2014 May 19.

17.

Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control.

Yu Y, Liu L, Xie N, Xue H, Fazli L, Buttyan R, Wang Y, Gleave M, Dong X.

J Clin Endocrinol Metab. 2013 Jul;98(7):2887-96. doi: 10.1210/jc.2012-4000. Epub 2013 May 10.

18.

Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.

Godoy AS, Chung I, Montecinos VP, Buttyan R, Johnson CS, Smith GJ.

Am J Physiol Endocrinol Metab. 2013 Jun 1;304(11):E1131-9. doi: 10.1152/ajpendo.00602.2012. Epub 2013 Apr 2. Review.

19.

The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor.

Wang H, Jiang M, Cui H, Chen M, Buttyan R, Hayward SW, Hai T, Wang Z, Yan C.

Mol Cell Biol. 2012 Aug;32(16):3190-202. doi: 10.1128/MCB.00159-12. Epub 2012 Jun 4.

20.

Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders.

Glinskii AB, Ma S, Ma J, Grant D, Lim CU, Guest I, Sell S, Buttyan R, Glinsky GV.

Cell Cycle. 2011 Oct 15;10(20):3571-97. doi: 10.4161/cc.10.20.17842.

21.

Paracrine Hedgehog increases the steroidogenic potential of prostate stromal cells in a Gli-dependent manner.

Levina E, Chen M, Carkner R, Shtutman M, Buttyan R.

Prostate. 2012 Jun 1;72(8):817-24. doi: 10.1002/pros.21500. Epub 2011 Oct 24.

PMID:
22025366
22.

The hedgehog/Gli signaling paradigm in prostate cancer.

Chen M, Carkner R, Buttyan R.

Expert Rev Endocrinol Metab. 2011;6(3):453-467.

23.

Tumor-specific silencing of COPZ2 gene encoding coatomer protein complex subunit ζ 2 renders tumor cells dependent on its paralogous gene COPZ1.

Shtutman M, Baig M, Levina E, Hurteau G, Lim CU, Broude E, Nikiforov M, Harkins TT, Carmack CS, Ding Y, Wieland F, Buttyan R, Roninson IB.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12449-54. doi: 10.1073/pnas.1103842108. Epub 2011 Jul 11.

24.

Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells.

Tanner MJ, Welliver RC Jr, Chen M, Shtutman M, Godoy A, Smith G, Mian BM, Buttyan R.

PLoS One. 2011 Jan 18;6(1):e16027. doi: 10.1371/journal.pone.0016027.

25.

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A.

Cancer Res. 2010 Nov 15;70(22):9253-64. doi: 10.1158/0008-5472.CAN-10-1447. Epub 2010 Nov 2.

26.

Gli2 expression and human bladder transitional carcinoma cell invasiveness.

Mechlin CW, Tanner MJ, Chen M, Buttyan R, Levin RM, Mian BM.

J Urol. 2010 Jul;184(1):344-51. doi: 10.1016/j.juro.2010.03.007. Epub 2010 May 20.

PMID:
20488474
27.

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.

Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, Tanner MJ, Shtutman M, Vacherot F, Terry S, de la Taille A, Buttyan R.

Mol Cancer. 2010 Apr 26;9:89. doi: 10.1186/1476-4598-9-89.

28.

Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.

Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissière-Michot F, Maillé P, Kheuang L, Coppolani E, Ali A, Bibeau F, Culine S, Buttyan R, de la Taille A, Vacherot F.

Br J Cancer. 2009 Sep 15;101(6):951-6. doi: 10.1038/sj.bjc.6605245. Epub 2009 Aug 18.

29.

beta-carboline alkaloid-enriched extract from the amazonian rain forest tree pao pereira suppresses prostate cancer cells.

Bemis DL, Capodice JL, Desai M, Katz AE, Buttyan R.

J Soc Integr Oncol. 2009 Spring;7(2):59-65.

PMID:
19476740
30.

Differential expression of vascular endothelial growth factor, and angiopoietin 1 and 2 in functionally divergent experimental rabbit models of bladder hypertrophy.

Walker A, Tanner MJ, Husson P, Schuler C, Kogan BA, Buttyan R, Levin RM.

J Urol. 2009 Jun;181(6):2790-6. doi: 10.1016/j.juro.2009.01.100. Epub 2009 Apr 17.

PMID:
19375749
31.

Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells.

Chen M, Tanner M, Levine AC, Levina E, Ohouo P, Buttyan R.

Cell Cycle. 2009 Jan 1;8(1):149-57.

32.

Editorial comment on: Hedgehog signalling in androgen independent prostate cancer.

Chen M, Buttyan R.

Eur Urol. 2008 Dec;54(6):1341-3. doi: 10.1016/j.eururo.2008.01.071. Epub 2008 Feb 4. No abstract available.

PMID:
18262714
33.

The Wnt/beta-catenin pathway in Wilms tumors and prostate cancers.

Tycko B, Li CM, Buttyan R.

Curr Mol Med. 2007 Aug;7(5):479-89. Review.

PMID:
17691963
34.

Molecularly targeted therapies for renal cell cancer: TRAIL research advances.

Buttyan R, Mian BM.

J Urol. 2007 May;177(5):1606. No abstract available.

PMID:
17437767
35.
36.

Anti-prostate cancer activity of a beta-carboline alkaloid enriched extract from Rauwolfia vomitoria.

Bemis DL, Capodice JL, Gorroochurn P, Katz AE, Buttyan R.

Int J Oncol. 2006 Nov;29(5):1065-73.

PMID:
17016636
37.

Clinical trials of natural products as chemopreventive agents for prostate cancer.

Bemis DL, Katz AE, Buttyan R.

Expert Opin Investig Drugs. 2006 Oct;15(10):1191-200. Review.

PMID:
16989596
38.

Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.

Terry S, Yang X, Chen MW, Vacherot F, Buttyan R.

J Cell Biochem. 2006 Oct 1;99(2):402-10. Review.

PMID:
16741972
39.

[Protocadherin-PC discovery and its implication in prostate cancer progression].

Vacherot F, Terry S, Faucon H, Queires L, Chen MW, Yang X, Gil Diez de Medina S, Verdier A, Azoulay S, Allory Y, Abbou CC, Buttyan R, de la Taille A.

Prog Urol. 2005 Dec;15(6 Suppl 1):1294-302. Review. French. No abstract available.

PMID:
16734220
40.

Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors.

Gilbert SM, Whitson JM, Mansukhani M, Buttyan R, Benson MC, Olsson CA, Sawczuk IS, McKiernan JM.

Urology. 2006 May;67(5):942-5.

PMID:
16698354
41.

Protocadherin-PC promotes androgen-independent prostate cancer cell growth.

Terry S, Queires L, Gil-Diez-de-Medina S, Chen MW, de la Taille A, Allory Y, Tran PL, Abbou CC, Buttyan R, Vacherot F.

Prostate. 2006 Jul 1;66(10):1100-13.

42.

The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer.

Bemis DL, Capodice JL, Costello JE, Vorys GC, Katz AE, Buttyan R.

Curr Urol Rep. 2006 May;7(3):166-74. Review.

PMID:
16630519
43.

The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer.

Bemis DL, Capodice JL, Costello JE, Vorys GC, Katz AE, Buttyan R.

Curr Oncol Rep. 2006 May;8(3):228-36. Review.

PMID:
16618388
44.

Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells.

Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, Capodice J, Kitajewski J, de la Taille A, Benson MC, Guo Y, Buttyan R.

Oncogene. 2006 Jun 8;25(24):3436-44. Epub 2006 Feb 13. Erratum in: Oncogene. 2006 Jul 13;25(30):4256.

45.

Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndrome.

Capodice JL, Bemis DL, Buttyan R, Kaplan SA, Katz AE.

Evid Based Complement Alternat Med. 2005 Dec;2(4):495-501. Epub 2005 Oct 10.

46.
47.

Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis.

Burchardt M, Burchardt T, Anastasiadis AG, Buttyan R, de la Taille A, Shabsigh A, Frank J, Shabsigh R.

Urology. 2005 Sep;66(3):665-70.

PMID:
16140112
48.

A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.

Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL, Kitajewski J, Benson MC, Guo Y, Buttyan R.

Cancer Res. 2005 Jun 15;65(12):5263-71.

49.

A problem with a chaperone.

Lamb DJ, Zhang L, Buttyan R.

J Urol. 2005 May;173(5):1455. No abstract available.

PMID:
15821459
50.

Role of angiogenesis in bladder response to partial outlet obstruction.

Levin R, Chichester P, Levin S, Buttyan R.

Scand J Urol Nephrol Suppl. 2004;(215):37-47. Review.

PMID:
15545195

Supplemental Content

Loading ...
Support Center